A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics (explores
what the body does to the drug) of JNJ-37822681 in participants with stable schizophrenia
(psychiatric disorder with symptoms of emotional instability, detachment from reality, often
with delusions and hallucinations, and withdrawal into the self).
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.